Thanks, Matt.
significant starts. challenges continue its the to we disease on I And note as consistent patients the generate driven DMD nonsense in market with for despite Translarna provide first it continue continued only franchise team by new both for fourth underlying Emflaza. the mutation to we quarter that EU, our revenue Translarna our commercial to in long in including and with products, remains and performance DMD to and Our in-line had will remains strong want quarter the revenue levels therapy as patient have XXXX treat the authorized. the even results
Matt rapidly under As U.S. approval. positioned review experienced to pending currently is potential is to bring FDA, Translarna mentioned, well and our by Translarna team patients
solid as see Our brand loyalty patients from and Emflaza continued was performance caregivers. physicians, we
year for new product Emflaza our U.S. expand may there X launches. erosion defend future While generic we brand neurology with prepare potential we as to in to the this successfully be continue entries, portfolio
PKU. Moving for to sepiapterin
actively the We Japan key launches global Germany, are potential and preparing other for upcoming U.S., in countries. the
where PKU addressable We key markets are is focusing available. reimbursement approximately therapies medical with of on XX,XXX patients
those represents a months coordinate the strategic U.S. of medical in are launch.
The most address whom restrictive sequence current who for therapies first and failed of other without sepiapterin approximately vast patients those, are largest any treatments. supports with potential all will and segments, not were or We tried including of sepiapterin patients have classical to targeting therapies therapy-naive failed well launch sepiapterin PKU already highly Of current patients, patients who a specific these a than options and patients PKU. patients, on The efficacy with XX,XXX patient XX including diet. or therapies, not for opportunity of poorly tolerating are access majority the majority existing currently clinical a PKU have treatment its controlled controlled
upcoming metabolic of children with practitioners Our diagnosed the are parents stakeholders the and and are instrumental excellence launch decisions this health profiling are include who nurse with stakeholders when and dietitians first meeting early. actively customer-facing in to key care teams treatment main contact and preparation of medical summer. These of centers often line professionals,
they addition, also well provide into adulthood. of their care In long-term continuity
key in Our commercial of sepiapterin. successful launch for pillars place are
population, screening, along treatment. well-diagnosed is to these are of the First, even medical are their tied on many manage closely patient not to disease, newborn currently centers with excellence patients and a there if prevalent
need positions and challenges to vast Phe more efficacy rapidly of mechanism broad become clinically patients levels and who effective consequences Second, neurocognitive patients PKU Sepiapterin of many of a improves care. therapy, the meaningful restrictions of allowing patients controlled standard sepiapterin's across have PKU potential with Phe poorly dual majority action of the well-differentiated in dietary population to disease. the its of the overcome future lowering, of
to potentially receive therapy. the sepiapterin presented has the Third, clearly of more many been time who patients via can payers proposition lab for profile control Phe be measured that clinical to reducing the value understand of effective rapidly testing,
leveraging sepiapterin the has With to PTC's revenue we disease, these exceed in billion infrastructure in believe $X place and rare experienced for commercial pillars potential opportunity. global
patients. unmet for FA, where program is vatiquinone for to turning need all a Now, significant there
a United following approved there FA approval indicated XX potential team upcoming our for commercial neurology summer. expand of U.S. an all prevalence patients. many only is States, The awareness, Our therapy with launch portfolio older. to which and patients. estimated this them no whom preparing for increase In the is pediatric are patients is years X/X experience current and an X,XXX there raising FA in of disease diagnosis, of has especially therapy.
PTC is can approved for in neurology, earlier About benefiting FDA
cannot therapy an time these well-differentiated awareness and FA neurological exciting introduce patients. diagnosis There of provide rare currently to an for to will vatiquinone commercial therapy. option product and current safety this first mechanism patients financial that, believe education throughout sooner tolerate now who This for and important is over can disease the potential believe the for efficacy year.
With more And turn adults for with treatment suffering providing Pierre? to from a or long-term Pierre With vatiquinone's at launches FA FA, very opportunity age, will devastating and team disease. only many action earlier with a to slow multiple an progression call as prepare on the for in as occur new our with also opportunity update. disease we the are I move global we we children not are
